Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Why the study?
Does adding trastuzumab to neoadjuvant chemotherapy improve pathologic complete response in patients with HER2-positive operable breast cancer?
Population
42 patients with human epidermal growth factor receptor 2 (HER2)-positive operable breast cancer
Comparison
Four cycles of paclitaxel followed by four… vs Four cycles of paclitaxel followed by four…
Design
RCT, randomly assigned
Follow-up
24 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports adding trastuzumab to neoadjuvant chemotherapy for HER2-positive operable breast cancer; extends randomized evidence for improved responses.
Structured PICO
Does adding trastuzumab to neoadjuvant chemotherapy improve pathologic complete response in patients with HER2-positive operable breast cancer?
P
Population
42 patients with human epidermal growth factor receptor 2 (HER2)-positive operable breast cancer
I
Intervention
Four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide with simultaneous weekly trastuzumab for 24 weeks
C
Comparator
Four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide
O
Outcome
Pathologic complete response (pCR) ratesurrogate
Adding trastuzumab to neoadjuvant chemotherapy significantly increases pathologic complete response rates in HER2-positive operable breast cancer without inducing clinical congestive heart failure.
Limitations
- small sample size
Cite This Study
Buzdar et al. (2005) studied this question.